GUT-103

**GUT-103** is a rationally designed live bacterial consortium consisting of 17 metabolically interdependent strains isolated from healthy human stool samples, developed by Gusto Global for treating inflammatory bowel disease (IBD). It synergistically provides redundant therapeutic functionalities, including mucosal homeostasis, immune modulation, pathobiont competition via bacteriocins, short-chain fatty acid (SCFA) production like butyrate and propionate, and secondary bile acid metabolism (e.g., LCA, DCA), to restore functional gut microbiome dysbiosis in inflamed environments. In preclinical gnotobiotic and humanized mouse models of Th1/Th17-mediated colitis mimicking Crohn's disease, oral GUT-103 rapidly colonized the colon, outcompeted colitogenic pathobionts (e.g., adherent-invasive E. coli, Ruminococcus gnavus), reduced inflammation (e.g., lower IFNγ, IL-12p40, TNFα), promoted regulatory immunity (e.g., IL-10-producing T cells, Tregs), increased protective metabolites, and demonstrated both preventive and therapeutic efficacy by reversing established colitis without inducing inflammation.[1][2][3][5]